CRVO: CervoMed Inc

CRVO新闻

• 12:24 Cantor Fitzgerald 给予 CervoMed 股票"增持"评级
• 12:23 Cantor Fitzgerald initiates CervoMed stock with Overweight rating
• 22:15 CervoMed股价在有前景的痴呆症药物试验结果后飙升
• 22:12 CervoMed的路易体痴呆症药物在2b期临床试验中显示前景
• 22:10 CervoMed’s DLB drug shows promise in phase 2b trial
• 22:09 CervoMed stock soars after promising dementia drug trial results
• 12:16 Neflamapimod reduces key neurodegeneration markers in DLB study
• 12:54 CervoMed Inc.：首席商务官Winton购入价值4.143万美元CRVO股票
• 12:54 CervoMed首席执行官Alam购买价值182,736美元的股票
• 12:54 葛雷瓜尔·西尔维以182,736美元购入CervoMed (CRVO)股票
• 12:53 威廉·埃尔德购买价值$29,250的CervoMed (CRVO)股票
• 22:55 CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
• 11:45 Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
• 13:50 Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates
• 06:44 This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Boise Cascade (NYSE:BCC), CervoMed (NASDAQ:CRVO)
• 13:28 CervoMed股价在FDA认可三期临床试验设计后上涨
• 13:28 CervoMed stock rises after FDA alignment on Phase 3 trial design
• 12:05 FDA aligns with CervoMed on phase 3 trial design for DLB treatment